阿尔茨海默病市场的下一个十亿美元机遇：值得关注的6种在研疗法 DelveInsight-动脉网

The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch

CISION 等信源发布 2026-08-06 22:31



可切换为仅中文







The Alzheimer's disease market dynamics are anticipated to change due to the expected launch of emerging therapies, such as Masupirdinea (Suven Life Sciences), Trontinemabb (Roche), Buntanetap (Annovis bio), Masitinib (AB Science), Remternetug (Eli Lilly), AUVELITY (AXS-05) (Axsome Therapeutics), Bezisterim (NE3107) (Biovie), Valiltramiprosate (ALZ-801) (ALZHEON), Hydromethylthionine mesylate (HMTM) (TRx0237) (TauRx Therapeutics), COBENFY (KarxXT) (Bristol Myers Squibb), AR1001d (AriBio), Remlifanserin (ACP.

阿尔茨海默病市场的动态预计将因新兴疗法的预期上市而发生变化，这些疗法包括：Masupirdinea（Suven Life Sciences）、Trontinemabb（罗氏）、Buntanetap（Annovis Bio）、Masitinib（AB Science）、Remternetug（礼来）、AUVELITY（AXS-05）（Axsome Therapeutics）、Bezisterim（NE3107）（Biovie）、Valiltramiprosate（ALZ-801）（ALZHEON）、Hydromethylthionine mesylate（HMTM）（TRx0237）（TauRx Therapeutics）、COBENFY（KarXT）（百时美施贵宝）、AR1001d（AriBio）以及Remlifanserin（ACP。

‑

204) (Acadia Pharmaceuticals), Tricaprilin (Cerecin), and others, and others.

204)（Acadia Pharmaceuticals）、三癸酸甘油酯（Cerecin）等。

LAS VEGAS

拉斯维加斯

，

Aug. 6, 2026

2026年8月6日

/PRNewswire/ -- The Alzheimer's disease treatment landscape is experiencing a major transformation with the introduction of disease-modifying therapies that target fundamental disease mechanisms, particularly amyloid-β pathology. Among these,

/美通社/ -- 随着针对疾病根本机制（尤其是β-淀粉样蛋白病理）的疾病修饰疗法的问世，阿尔茨海默病治疗格局正经历重大变革。其中，

LEQEMBI (lecanemab)

LEQEMBI（lecanemab）

has become a leading biologic for patients with early-stage Alzheimer's disease, demonstrating its ability to slow cognitive and functional deterioration in biomarker-confirmed individuals. Regulatory approvals across key global markets have strengthened the shift toward earlier diagnosis, timely intervention, and biologically targeted treatment approaches. .

已成为早期阿尔茨海默病患者的领先生物制剂，展现出其在经生物标志物确认的个体中延缓认知和功能衰退的能力。全球主要市场的监管批准进一步加强了向早期诊断、及时干预和生物靶向治疗方法的转变。

Furthermore, the approval of

此外，批准

LEQEMBI IQLIK

, a subcutaneous maintenance formulation, is anticipated to enhance patient convenience by allowing at-home or simplified administration, reducing reliance on infusion-based therapy. Likewise,

，一种皮下维持制剂，预计将通过允许居家或简化给药来提高患者便利性，减少对输注治疗的依赖。同样，

KISUNLA (donanemab)

KISUNLA（多奈单抗）

has emerged as another important anti-amyloid monoclonal antibody, offering clinically meaningful reductions in disease progression while distinguishing itself through the potential to discontinue treatment after achieving amyloid plaque clearance.

已成为另一种重要的抗淀粉样蛋白单克隆抗体，能够在临床上显著减缓疾病进展，并凭借在实现淀粉样斑块清除后有望停药这一特点而脱颖而出。

Discover more about the Alzheimer's disease therapeutics market @

了解更多关于阿尔茨海默病治疗市场的信息 @

https://www.delveinsight.com/report-store/alzheimers-disease-ad-market

While disease-modifying biologics are reshaping therapeutic strategies, symptomatic treatments remain integral to the clinical management of Alzheimer's disease.

尽管疾病修饰性生物制剂正在重塑治疗策略，但对症治疗仍然是阿尔茨海默病临床管理的重要组成部分。

ZUNVEYL (benzgalantamine)

ZUNVEYL（苯加兰他敏）

, a next-generation oral acetylcholinesterase inhibitor (AChEI), has been developed to improve gastrointestinal tolerability and long-term treatment adherence. Similarly,

，一种下一代口服乙酰胆碱酯酶抑制剂（AChEI），已被开发出来以改善胃肠道耐受性和长期治疗依从性。同样地，

ALLYDONE

盟友完成

transdermal donepezil patches provide an alternative drug delivery option designed to improve compliance, particularly among elderly patients.

经皮多奈哌齐贴剂提供了一种替代给药方案，旨在提高患者的依从性，尤其是在老年患者中。

In addition,

此外，

REXULTI (brexpiprazole)

雷克西提（布瑞哌唑）

has broadened the treatment landscape by addressing agitation associated with Alzheimer's disease dementia, reflecting the growing emphasis on managing both cognitive impairment and neuropsychiatric symptoms. Collectively, the combination of disease-modifying monoclonal antibodies with enhanced symptomatic and behavioral therapies is expected to redefine Alzheimer's disease management by promoting earlier intervention, personalized care, and a more comprehensive treatment approach..

通过解决与阿尔茨海默病痴呆相关的激越症状，拓宽了治疗格局，反映出日益重视同时管理认知障碍和神经精神症状的趋势。总体而言，疾病修饰性单克隆抗体与增强的对症及行为疗法相结合，有望通过促进早期干预、个性化护理以及更全面的治疗策略，重新定义阿尔茨海默病的管理模式。

Sadaf Javed, Functional Head of Forecasting & Analytics at DelveInsight, said there is an opportunity for companies to conduct trials evaluating safer therapies with convenient patient doses at low cost that can enhance treatment compliance and adherence.

DelveInsight 预测与分析部门负责人 Sadaf Javed 表示，企业有机会开展低成本临床试验，评估具有便捷给药方案且更安全的疗法，从而提高患者的治疗依从性和遵从性。

Beyond currently available therapies, the late-stage Alzheimer's disease pipeline continues to diversify, with multiple investigational candidates employing mechanisms that extend beyond conventional amyloid-focused strategies, highlighting the field's evolving emphasis on targeting complementary pathological pathways.

在现有疗法之外，阿尔茨海默病晚期研发管线持续多元化，多种在研候选药物采用的机制超越了传统的以淀粉样蛋白为中心的策略，凸显了该领域日益重视针对互补病理通路的趋势。

Key candidates include .

主要候选人包括。

Masupirdinea

马苏皮迪内亚

(Suven Life Sciences),

（Suven Life Sciences），

Trontinemabb

特龙替单抗

(Roche),

（罗氏）

Buntanetap

布坦内塔普

(Annovis bio),

(Annovis Bio)

Masitinib

马西替尼

(AB Science),

（AB Science）

Remternetug

雷特奈鲁格

(Eli Lilly),

（礼来公司）

AUVELITY (AXS-05)

AUVELITY（AXS-05）

(Axsome Therapeutics),

（Axsome Therapeutics）

Bezisterim (NE3107)

贝齐斯特林（NE3107）

(Biovie),

Valiltramiprosate (ALZ-801)

缬氨曲米多酯（ALZ-801）

(ALZHEON),

（ALZHEON）

Hydromethylthionine mesylate (HMTM) (TRx0237)

甲磺酸氢甲基硫堇（HMTM）（TRx0237）

(TauRx Therapeutics),

COBENFY (KarxXT)

COBENFY（KarxXT）

(Bristol Myers Squibb),

（百时美施贵宝）

AR1001d

(AriBio),

（AriBio）

Remlifanserin (ACP

雷姆利凡塞林（ACP

‑

204)

(Acadia Pharmaceuticals),

（阿卡迪亚制药公司）

Tricaprilin

三癸酸甘油酯

(Cerecin), and others.

（Cerecin）等。

Reflecting sustained innovation and expanding commercial opportunities, DelveInsight estimates that the Alzheimer's disease market across the seven major markets, comprising the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, was valued at approximately

反映出持续的创新和不断扩大的商业机会，DelveInsight估计，阿尔茨海默病市场在七个主要市场（包括美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本）的规模约为

USD 4 billion

40亿美元

in 2025. The market is projected to expand at a

在2025年。预计市场将以

CAGR of 22.7%

复合年增长率（CAGR）为22.7%

during the forecast period through 2036, driven by increasing disease prevalence, broader adoption of disease-modifying therapies, advancements in biomarker-based diagnosis, and a robust late-stage pipeline focused on improving clinical outcomes.

在截至2036年的预测期内，受疾病患病率上升、疾病修饰疗法的广泛采用、基于生物标志物的诊断技术进步以及旨在改善临床结果的强劲后期研发管线的推动。

Below, we highlight 6 emerging late-stage therapies poised to enter the Alzheimer's disease therapeutics market.

下文重点介绍6种即将进入阿尔茨海默病治疗市场的新兴后期疗法。

Suven Life Sciences' Masupirdine

Suven生命科学公司的Masupirdine

5-HT6 antagonist

5-HT6受体拮抗剂

Masupirdine (SUVN-502)

马斯匹定（SUVN-502）

is an investigational small-molecule candidate from

是一种处于研究阶段的小分子候选药物，来自

Suven Life Sciences

苏文生命科学公司

that is being developed to treat cognitive impairment and neuropsychiatric manifestations, particularly agitation, in patients with Alzheimer's disease. As a highly selective serotonin 5-HT6 receptor antagonist, Masupirdine is designed to enhance the release of neurotransmitters involved in cognition and behavioral regulation, to improve cognitive performance as well as neuropsychiatric symptoms..

该药物正在开发中，旨在治疗阿尔茨海默病患者的认知障碍和神经精神症状，尤其是激越症状。作为高选择性的5-羟色胺5-HT6受体拮抗剂，Masupirdine旨在增强参与认知和行为调节的神经递质的释放，从而改善认知功能以及神经精神症状。

In contrast to conventional treatment approaches that may be associated with sedation, Masupirdine is intended to offer a non-sedating therapeutic option by selectively modulating central serotonergic pathways. The therapy is being investigated to address significant unmet needs in Alzheimer's disease, especially for agitation and aggression, where effective and well-tolerated treatment options remain limited..

与可能引起镇静的传统治疗方法不同，Masupirdine 旨在通过选择性调节中枢血清素能通路，提供一种非镇静的治疗选择。该疗法正在研究中，以满足阿尔茨海默病领域尚未被满足的重大需求，尤其是针对激越和攻击性症状，目前针对这些症状的有效且耐受性良好的治疗选择仍然有限。

Masupirdine is currently being assessed in a global Phase III clinical trial evaluating its efficacy in treating agitation associated with Alzheimer's disease dementia. The study is expected to conclude by the end of 2026, with topline results anticipated during the first half of 2027. In June 2026, Suven Life Sciences announced encouraging results from a pre-specified interim analysis and an independent review by the Data and Safety Monitoring Board (DSMB), supporting the continuation of the Phase III development program..

Masupirdine 目前正在一项全球 III 期临床试验中接受评估，以评价其治疗阿尔茨海默病痴呆相关激越症状的疗效。该研究预计将于 2026 年底结束，主要结果有望在 2027 年上半年公布。2026 年 6 月，Suven Life Sciences 宣布了一项预先指定的中期分析和数据与安全监查委员会（DSMB）独立审查的积极结果，支持继续推进 III 期开发计划。

According to Javed, Masupirdine has demonstrated a favorable safety and tolerability profile, reinforcing its potential as a therapeutic candidate. However, its ultimate success will depend on optimized clinical trial execution and appropriate patient selection. While the therapy holds considerable promise, additional clinical validation will be essential to confirm its efficacy and support future regulatory approval..

据贾维德称，Masupirdine 已展现出良好的安全性和耐受性特征，这进一步巩固了其作为治疗候选药物的潜力。然而，其最终成功将取决于临床试验的优化执行以及合适的患者选择。尽管该疗法前景广阔，但仍需进一步的临床验证以确认其疗效，并为未来的监管审批提供支持。

Roche's Trontinemab

罗氏的Trontinemab

Aβ-protein Inhibitors

Aβ蛋白抑制剂

Trontinemab (RG6102)

特龙替尼单抗（RG6102）

is an investigational bispecific monoclonal antibody engineered with Brainshuttle technology to enhance the delivery of anti-amyloid therapies across the blood–brain barrier for the treatment of Alzheimer's disease. It selectively binds aggregated amyloid-beta (Aβ) and is designed to promote rapid and robust clearance of amyloid plaques from the brain..

是一种采用Brainshuttle技术 engineered 的在研双特异性单克隆抗体，旨在增强抗淀粉样蛋白疗法跨越血脑屏障的递送能力，用于治疗阿尔茨海默病。它选择性结合聚集态的β-淀粉样蛋白（Aβ），旨在促进大脑中淀粉样斑块的快速且强效清除。

The therapy integrates an anti-Aβ antibody with

该疗法将一种抗Aβ抗体与

Roche's proprietary Transferrin Receptor 1 (TfR1)-mediated Brainshuttle platform

罗氏专有的转铁蛋白受体1（TfR1）介导的Brainshuttle平台

, which improves transport into the central nervous system. By increasing brain exposure at lower doses than conventional anti-amyloid antibodies, trontinemab has the potential to accelerate and enhance amyloid plaque removal. This improved brain penetration may amplify the disease-modifying effects of amyloid-targeting therapies and help slow the progression of Alzheimer's disease.

，从而改善向中枢神经系统的转运。与传统的抗淀粉样蛋白抗体相比，特罗尼单抗在更低剂量下即可增加大脑暴露量，有望加速并增强淀粉样蛋白斑块的清除。这种增强的脑部渗透性可能会放大靶向淀粉样蛋白疗法的疾病修饰作用，并有助于延缓阿尔茨海默病的进展。

According to Roche, regulatory filings for trontinemab are currently expected after 2028..

据罗氏称，特罗尼单抗的监管申报预计将在2028年之后进行。

Explore more about recent advancements in Alzheimer's disease-modifying treatments @

探索阿尔茨海默病疾病修饰疗法的最新进展 @

Timeline of Alzheimer's Disease Treatment

阿尔茨海默病治疗时间线

Axsome Therapeutics' AXS-05

Axsome Therapeutics 的 AXS-05

NMDA receptor Antagonist

NMDA受体拮抗剂

AXS-05

is an investigational oral therapy engineered with a multimodal mechanism of action to address disorders of the central nervous system (CNS). It combines dextromethorphan and bupropion in a proprietary formulation that is designed to optimize the pharmacological activity of dextromethorphan. As part of its mechanism, dextromethorphan acts as both an .

是一种研究性口服疗法，采用多模式作用机制设计，旨在治疗中枢神经系统（CNS）疾病。该疗法将右美沙芬和安非他酮结合于专有配方中，旨在优化右美沙芬的药理活性。在其作用机制中，右美沙芬同时作为一种

N-methyl-D-aspartate (NMDA) receptor antagonist and a sigma-1 receptor agonist

N-甲基-D-天冬氨酸（NMDA）受体拮抗剂和σ-1受体激动剂

, helping regulate glutamatergic signaling and neuronal communication implicated in CNS disorders.

，有助于调节与中枢神经系统疾病相关的谷氨酸能信号传导和神经元通讯。

The NMDA receptor is essential for synaptic function, learning, memory, and neuronal plasticity, and abnormalities in this pathway have been linked to a range of neurodegenerative and neuropsychiatric conditions. By modulating these signaling pathways, AXS-05 represents a promising therapeutic approach for disorders associated with cognitive dysfunction and behavioral disturbances..

NMDA受体对于突触功能、学习、记忆和神经元可塑性至关重要，该通路的异常与一系列神经退行性疾病和神经精神疾病相关。通过调节这些信号通路，AXS-05为治疗与认知功能障碍和行为障碍相关的疾病提供了一种前景广阔的治疗方案。

The therapy is currently under clinical investigation for several indications, including agitation related to Alzheimer's disease and smoking cessation. While these uses have not yet been approved by the U.S. FDA, AXS-05 has received

该疗法目前正针对多种适应症进行临床研究，包括与阿尔茨海默病相关的激越症状以及戒烟。尽管这些用途尚未获得美国食品药品监督管理局（FDA）的批准，但AXS-05已获得

Breakthrough Therapy Designation

突破性疗法认定

for the treatment of agitation associated with Alzheimer's disease. This designation highlights its potential to address a substantial unmet medical need by improving the management of neuropsychiatric symptoms in individuals living with Alzheimer's disease.

用于治疗与阿尔茨海默病相关的激越症状。这一认定凸显了其在改善阿尔茨海默病患者神经精神症状管理方面的潜力，从而有望满足重大的未竟医疗需求。

Bristol Myers Squibb's COBENFY

百时美施贵宝的COBENFY

Muscarinic M1/M4 receptor agonist

毒蕈碱M1/M4受体激动剂

COBENFY (KarXT; xanomeline–trospium chloride)

COBENFY（KarXT；卡诺美林–氯化托哌酮）

is a novel

是一部小说

muscarinic receptor-targeting

靶向毒蕈碱受体

therapy

治疗

under investigation for the treatment of Alzheimer's disease psychosis (ADP). In contrast to traditional antipsychotics, which primarily exert their effects through dopamine receptor antagonism, COBENFY selectively stimulates M1 and M4 muscarinic acetylcholine receptors within the central nervous system.

正在接受阿尔茨海默病精神病（ADP）治疗的研究。与主要通过多巴胺受体拮抗作用发挥疗效的传统抗精神病药物不同，COBENFY 选择性刺激中枢神经系统内的 M1 和 M4 型毒蕈碱乙酰胆碱受体。

This differentiated mechanism aims to alleviate both psychotic and cognitive symptoms associated with Alzheimer's disease while potentially reducing the risk of adverse effects commonly linked to dopamine-blocking therapies. Administered orally, COBENFY represents an innovative therapeutic strategy within the evolving Alzheimer's disease treatment landscape..

这种差异化机制旨在缓解与阿尔茨海默病相关的精神病性症状和认知症状，同时可能降低与多巴胺阻断疗法常见的不良反应风险。COBENFY 为口服给药，代表了在不断发展的阿尔茨海默病治疗格局中的一种创新治疗策略。

COBENFY is currently advancing through Phase III clinical development for Alzheimer's disease psychosis, with topline results anticipated in 2026. Beyond psychosis, the therapy is also being evaluated for additional Alzheimer's disease-related conditions, including agitation and cognitive impairment, highlighting its potential as a broad-spectrum neuropsychiatric treatment..

COBENFY 目前正处于针对阿尔茨海默病所致精神病的 III 期临床开发阶段，预计将于 2026 年公布主要结果。除了精神病症状外，该疗法也在评估用于其他与阿尔茨海默病相关的病症，包括激越和认知障碍，这凸显了其作为广谱神经精神治疗药物的潜力。

The ongoing

正在进行的

ADEPT-1, ADEPT-2, and ADEPT-4 Phase III studies

ADEPT-1、ADEPT-2 和 ADEPT-4 的 III 期研究

are expected to deliver topline results for Alzheimer's disease psychosis in 2026. If these studies are successful and regulatory approvals are secured, COBENFY could reach the market as early as 2027. In Alzheimer's disease agitation, the Phase III ADAGIO-2 trial is projected to report results in 2028, which could support a commercial launch beginning in 2029.

预计将于2026年公布阿尔茨海默病精神病性症状的顶层研究结果。如果这些研究取得成功并获得监管批准，COBENFY最早可能在2027年上市。在阿尔茨海默病激越方面，III期ADAGIO-2试验预计将于2028年报告结果，这可能支持其于2029年开始商业化上市。

Additionally, the .

此外，.

MINDSET-1 and MINDSET-2 trials

MINDSET-1 和 MINDSET-2 试验

are assessing the therapy's impact on cognitive impairment associated with Alzheimer's disease. These studies are also expected to report findings in 2028, with commercialization potentially commencing in 2029, subject to favorable clinical outcomes and regulatory clearance.

正在评估该疗法对阿尔茨海默病相关认知障碍的影响。预计这些研究也将于2028年公布结果，若临床试验结果良好并获得监管批准，商业化有望于2029年启动。

According to Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, COBENFY (KarXT) introduces a differentiated, non-dopaminergic approach to managing neuropsychiatric manifestations of Alzheimer's disease by selectively targeting central M1 and M4 muscarinic receptors. This mechanism may overcome some of the safety challenges associated with conventional antipsychotic therapies.

据DelveInsight预测与分析项目经理Aparna Thakur表示，COBENFY（KarXT）通过选择性靶向中枢M1和M4毒蕈碱受体，为管理阿尔茨海默病的神经精神症状引入了一种差异化的非多巴胺能方法。这种机制可能克服与传统抗精神病疗法相关的一些安全性挑战。

Its comprehensive Phase III clinical program spanning psychosis, agitation, and cognitive impairment underscores the company's strategy to establish COBENFY as a versatile, multi-indication treatment for neuropsychiatric complications in Alzheimer's disease..

其涵盖精神病、激越和认知障碍的全面III期临床项目，凸显了公司旨在将COBENFY确立为一种用于治疗阿尔茨海默病神经精神并发症的多用途、多适应症药物的战略。

To know more about Alzheimer's disease drug development, visit @

如需了解更多关于阿尔茨海默病药物研发的信息，请访问 @

Alzheimer's Disease Treatment Pipeline

阿尔茨海默病治疗研发管线

Eli Lilly's Remternetug

礼来公司的Remternetug

Aβ-protein Inhibitors

Aβ蛋白抑制剂

Remternetug (LY3372993)

Remternetug（LY3372993）

is an investigational monoclonal antibody being developed for the treatment of early-stage Alzheimer's disease. It is formulated for both intravenous (IV) and subcutaneous (SC) administration and selectively targets

是一种正在开发中的实验性单克隆抗体，用于治疗早期阿尔茨海默病。该药制剂适用于静脉注射（IV）和皮下注射（SC），并具有选择性靶向作用

N3pG amyloid-beta (Aβ)

N3pG淀粉样蛋白-β（Aβ）

, a modified amyloid species implicated in the disease's pathology. By binding to toxic amyloid plaques in the brain, the therapy promotes their clearance through immune-mediated mechanisms to slow disease progression. Remternetug has completed Phase I clinical studies and is currently undergoing Phase III clinical evaluation in patients with early Alzheimer's disease..

，一种与疾病病理机制相关的修饰型淀粉样蛋白。该疗法通过与脑内毒性淀粉样斑块结合，借助免疫介导的机制促进其清除，从而延缓疾病进展。Remternetug已完成I期临床研究，目前正处于针对早期阿尔茨海默病患者的III期临床评估阶段。

Thakur noted that remternetug underscores Eli Lilly's focus on advancing next-generation amyloid-targeting antibodies designed to improve patient convenience, particularly by enabling potential subcutaneous delivery and faster amyloid plaque clearance.

塔库尔指出，remternetug 突显了礼来公司致力于推进下一代靶向淀粉样蛋白抗体的研发，旨在提升患者便利性，特别是通过实现潜在的皮下给药和更快的淀粉样蛋白斑块清除。

Annovis Bio's Buntanetap

Annovis Bio 的 Buntanetap

Translational Inhibitor of Neurotoxic Aggregating Proteins (TINAPs)

神经毒性聚集蛋白的翻译抑制剂（TINAPs）

Buntanetap (previously known as ANVS401 or Posiphen)

Buntanetap（此前称为ANVS401或Posiphen）

is an orally available small-molecule therapy developed using a proprietary synthetic biochemical process. It represents a first-in-class group of therapeutics called

是一种采用专有合成生化工艺开发的口服小分子疗法。它代表了一类首创的治疗药物，称为

Translational Inhibitors of Neurotoxic Aggregating Proteins (TINAPs)

神经毒性聚集蛋白的翻译抑制剂（TINAPs）

, which are designed to suppress the production of multiple neurotoxic proteins involved in the progression of neurodegenerative diseases. By targeting several pathogenic proteins simultaneously, Buntanetap offers a differentiated mechanism of action with the potential to address the underlying pathology of these disorders..

，旨在抑制多种参与神经退行性疾病进展的神经毒性蛋白的产生。通过同时靶向多种致病蛋白，Buntanetap 提供了独特的作用机制，有望解决这些疾病的根本病理问题。

The therapy is being evaluated across a range of neurodegenerative indications, including Alzheimer's disease, Parkinson's disease, and Alzheimer's disease associated with Down syndrome. Buntanetap has completed a Phase II/III clinical trial in patients with mild-to-moderate Alzheimer's disease and is currently being assessed in a Phase III trial for individuals with early Alzheimer's disease, highlighting its potential to deliver therapeutic benefits across different stages of disease progression..

该疗法正在一系列神经退行性疾病适应症中进行评估，包括阿尔茨海默病、帕金森病以及与唐氏综合征相关的阿尔茨海默病。Buntanetap 已完成针对轻度至中度阿尔茨海默病患者的 II/III 期临床试验，目前正在进行针对早期阿尔茨海默病患者的 III 期试验评估，这凸显了其在疾病进展不同阶段提供治疗益处的潜力。

Download the report to understand the top emerging therapies in Alzheimer's Disease @

下载报告以了解阿尔茨海默病领域最前沿的新兴疗法 @

Alzheimer's Disease Drug Development Pipeline

阿尔茨海默病药物研发管线

Source: Alzheimer's Disease Market Report

来源：阿尔茨海默病市场报告

Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2036

阿尔茨海默病市场洞察、流行病学及市场预测 – 2036

report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including

报告深入解读了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和阿尔茨海默病领域的主要企业，包括

ARS Pharmaceuticals, Alfresa Pharma, Roche, Stallergenes Greer,

ARS Pharmaceuticals、Alfresa Pharma、罗氏、Stallergenes Greer，

DBV Technologies, Aquestive Therapeutics, Aravax, Siolta Therapeutics, GSK, Cue Biopharma, N-Fold, InnoUp Farma, Allergy Therapeutics, UKKO, Bryn Pharma, Poplar Therapeutics, Inimmune, Novartis (Excellergy), Intrommune Therapeutics, Regeneron Pharmaceuticals, Sanofi, Moonlight Therapeutics, Mabylon AG, Insignis Therapeutics, ALK-Abello, Cambridge Allergy, Prota Therapeutics.

DBV Technologies、Aquestive Therapeutics、Aravax、Siolta Therapeutics、葛兰素史克（GSK）、Cue Biopharma、N-Fold、InnoUp Farma、Allergy Therapeutics、UKKO、Bryn Pharma、Poplar Therapeutics、Inimmune、诺华（Excellergy）、Intrommune Therapeutics、再生元制药、赛诺菲、Moonlight Therapeutics、Mabylon AG、Insignis Therapeutics、ALK-Abello、Cambridge Allergy、Prota Therapeutics。

, and others.

，以及其他。

Related Reports